Eli Lilly: Credit Suisse downgrades to 'neutral'.

(CercleFinance.com) - Credit Suisse has downgraded its rating on the Eli Lilly stock from "outperform" to "neutral," while confirming its target price of 88 dollars, deeming that the stock has limited upside potential after its recent rise.


Indeed, the share of the US pharmaceutical group has risen by 13% since mid-August, Credit Suisse points out.

The Swiss bank expects flat revenues in 2018, before a return to growth, as well as a "significant expansion" in its operating margin.


Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.